Your session is about to expire
← Back to Search
DF6002 + Nivolumab for Advanced Cancer
Study Summary
This trial will test the safety and effectiveness of a new drug, DF6002, either alone or in combination with another drug, nivolumab, in people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had any cancer other than my current one in the last 3 years.My condition shows signs on exams or images.I need blood thinners for certain health risks.I have a serious heart condition or other major health issues.I have been diagnosed with a significant blood clotting disorder.I haven't had major surgery or taken steroids, other immune-weakening drugs, or experimental drugs in the last 28 days.My advanced cancer has no standard treatment left or treatments have failed.I am fully active or can carry out light work.I am not on any cancer treatments, immune therapies, or cytokine therapies except for erythropoietin.My cancer is growing quickly.My blood, liver, and kidney functions are all within normal ranges.
- Group 1: Monotherapy Dose Escalation
- Group 2: Combination Dose Escalation
- Group 3: Combination Dose Expansion (Melanoma)
- Group 4: Monotherapy Dose Expansion (Melanoma)
- Group 5: Monotherapy Dose Expansion (NSCLC)
- Group 6: Combination Dose Expansion (NSCLC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there multiple locations in the U.S. executing this research endeavor?
"For this clinical trial, patients can be enrolled at Lifespan - The Miriam Hospital in Providence, Rhode island, Roswell Park Comprehensive Cancer Center in Salt Lake City, Utah and Augusta University Georgia Cancer Centre in Augusta, Georgia with an additional 42 sites located across the United States."
What is the cap on participants in this clinical trial?
"This trial requires 473 suitable participants and is being conducted in several locations, such as Lifespan - The Miriam Hospital (Providence, Rhode island) and Roswell Park Comprehensive Cancer Center (Salt Lake City, Utah)."
Is this an experimental clinical trial?
"DF6002 has been undergoing trials since 2012, when it was initially sponsored by Ono Pharmaceutical Co. Ltd. After a successful Phase 1 and 2 approval process following the 659-participant trial in 2012, there are now 718 live studies being conducted across 49 nations with sites in 2356 cities."
Are there any unfilled slots in this clinical trial?
"Affirmative. The information on clinicaltrials.gov reveals that this investigation is seeking participants, having been first posted on July 10th 2020 and last amended November 1st 2022. 473 patients are needed for the trial which will take place in 42 different medical institutions."
What primary applications does DF6002 have?
"DF6002 is a commonly prescribed medication for treating malignant neoplasms. It has further shown promise in assisting with the management of unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
What prior research has been conducted regarding DF6002?
"DF6002 was first tested in 2012 at Local Institution. Presently, 252 studies have been finished and 718 are presently enrolling participants primarily from Providence, Rhode island."
Share this study with friends
Copy Link
Messenger